{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:29:01Z","timestamp":1790173741392,"version":"4.1.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>BACKGROUND<\/jats:title>\n                  <jats:p>The current standard for determining eligibility of patients with metastatic melanoma for BRAF-targeted therapy is tissue-based testing of BRAF mutations. As patients are rarely rebiopsied, detection in blood might be advantageous by enabling a comprehensive assessment of tumor mutational status in real time and thereby representing a noninvasive biomarker for monitoring BRAF therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>In all, 634 stage I to IV melanoma patients were enrolled at 2 centers, and 1406 plasma samples were prospectively collected. Patients were assigned to 3 separate study cohorts: study 1 for assessment of circulating tumor DNA (ctDNA) as part of companion diagnostics, study 2 for assessment of ctDNA for patients with low tumor burden and for follow-up, and study 3 for monitoring of resistance to BRAF inhibitor (BRAFi) or mitogen-activated protein kinase inhibitor therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Overall, a high degree of concordance between plasma and tissue testing results was observed at 90.9% (study 1) and 90.1% (study 2), respectively. Interestingly, discrepant results were in some cases associated with nonresponse to BRAFi (n = 3) or a secondary BRAF-mutant malignancy (n = 5). Importantly, ctDNA results correlated with the clinical course of disease in 95.7% and with response to treatment. Significantly, the detection of BRAF mutant ctDNA preceded relapse assessed by Response Evaluation Criteria in Solid Tumors, and was more specific than serum S100 and lactate dehydrogenase.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Blood-based testing compares favorably with standard-of-care tissue-based BRAF mutation testing. Importantly, blood-based BRAF testing correlates with the clinical course, even for early-stage patients, and may be used to predict response to treatment, recurrence, and resistance before radioimaging under BRAFi therapy, thereby enabling considerable improvements in patient treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1373\/clinchem.2017.281543","type":"journal-article","created":{"date-parts":[[2018,2,26]],"date-time":"2018-02-26T21:15:17Z","timestamp":1519679717000},"page":"830-842","source":"Crossref","is-referenced-by-count":63,"title":["Liquid Profiling of Circulating Tumor DNA in Plasma of Melanoma Patients for Companion Diagnostics and Monitoring of BRAF Inhibitor Therapy"],"prefix":"10.1093","volume":"64","author":[{"given":"Verena","family":"Haselmann","sequence":"first","affiliation":[{"name":"Department of Clinical Chemistry, University Medical Centre, Ruprecht-Karls University of Heidelberg, Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoffer","family":"Gebhardt","sequence":"first","affiliation":[{"name":"Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany"},{"name":"Department of Dermatology, Venereology and Allergology, University Medical Center, Ruprecht-Karls University of Heidelberg, Mannheim, Germany"},{"name":"Department of Dermatology and Venereology, University Hospital Hamburg-Eppendorf (UKE), Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Brechtel","sequence":"first","affiliation":[{"name":"Department of Clinical Chemistry, University Medical Centre, Ruprecht-Karls University of Heidelberg, Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Duda","sequence":"first","affiliation":[{"name":"Department of Clinical Chemistry, University Medical Centre, Ruprecht-Karls University of Heidelberg, Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Czerwinski","sequence":"first","affiliation":[{"name":"Department of Clinical Chemistry, University Medical Centre, Ruprecht-Karls University of Heidelberg, Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Sucker","sequence":"first","affiliation":[{"name":"Department of Dermatology, University of Essen Hospital, Essen, Germany and German Cancer Consortium (DKTK), Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Holland-Letz","sequence":"first","affiliation":[{"name":"German Cancer Research Center (DKFZ), Department of Biostatistics, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Utikal","sequence":"first","affiliation":[{"name":"Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany"},{"name":"Department of Dermatology, Venereology and Allergology, University Medical Center, Ruprecht-Karls University of Heidelberg, Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Schadendorf","sequence":"first","affiliation":[{"name":"Department of Dermatology, University of Essen Hospital, Essen, Germany and German Cancer Consortium (DKTK), Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Neumaier","sequence":"first","affiliation":[{"name":"Department of Clinical Chemistry, University Medical Centre, Ruprecht-Karls University of Heidelberg, Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,5,1]]},"reference":[{"key":"2020022606031248900_B1","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ab.2012.06.018","article-title":"Mutation-based detection and monitoring of cell-free tumor DNA in peripheral blood of cancer patients","volume":"433","author":"Benesova","year":"2013","journal-title":"Anal Biochem"},{"key":"2020022606031248900_B2","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1158\/2159-8290.CD-15-1336","article-title":"Application of sequencing, liquid biopsies, and patient-derived xenografts for personalized medicine in melanoma","volume":"6","author":"Girotti","year":"2016","journal-title":"Cancer Discov"},{"key":"2020022606031248900_B3","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","article-title":"A landscape of driver mutations in melanoma","volume":"150","author":"Hodis","year":"2012","journal-title":"Cell"},{"key":"2020022606031248900_B4","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"key":"2020022606031248900_B5","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (cobrim): updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol"},{"key":"2020022606031248900_B6","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"2020022606031248900_B7","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N Engl J Med"},{"key":"2020022606031248900_B8","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"},{"key":"2020022606031248900_B9","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/nm.1789","article-title":"Circulating mutant DNA to assess tumor dynamics","volume":"14","author":"Diehl","year":"2008","journal-title":"Nat Med"},{"key":"2020022606031248900_B10","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/j.cca.2011.07.011","article-title":"Methods for isolation of cell-free plasma DNA strongly affect DNA yield","volume":"412","author":"Fleischhacker","year":"2011","journal-title":"Clin Chim Acta"},{"key":"2020022606031248900_B11","doi-asserted-by":"crossref","first-page":"16368","DOI":"10.1073\/pnas.0507904102","article-title":"Detection and quantification of mutations in the plasma of patients with colorectal tumors","volume":"102","author":"Diehl","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2020022606031248900_B12","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa1213261","article-title":"Analysis of circulating tumor DNA to monitor metastatic breast cancer","volume":"368","author":"Dawson","year":"2013","journal-title":"N Engl J Med"},{"key":"2020022606031248900_B13","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2020022606031248900_B14","doi-asserted-by":"crossref","first-page":"9364","DOI":"10.1158\/0008-5472.CAN-07-0605","article-title":"Serial assessment of human tumor burdens in mice by the analysis of circulating DNA","volume":"67","author":"Rago","year":"2007","journal-title":"Cancer Res"},{"key":"2020022606031248900_B15","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1515\/cclm-2017-0283","article-title":"Results of the first external quality assessment scheme (EQA) for isolation and analysis of circulating tumour DNA (ctDNA)","volume":"56","author":"Haselmann","year":"2018","journal-title":"Clin Chem Lab Med"},{"key":"2020022606031248900_B16","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nmeth898","article-title":"BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions","volume":"3","author":"Diehl","year":"2006","journal-title":"Nat Methods"},{"key":"2020022606031248900_B17","unstructured":"Wellcome Trust Sanger Institute, Catalogue Of Somatic Mutation In Cancer (COSMIC). http:\/\/cancer.Sanger.Ac.Uk\/cancergenome\/projects\/cosmic. Accessed on October 2017."},{"key":"2020022606031248900_B18","doi-asserted-by":"crossref","first-page":"302ra133","DOI":"10.1126\/scitranslmed.aab0021","article-title":"Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer","volume":"7","author":"Garcia-Murillas","year":"2015","journal-title":"Sci Transl Med"},{"key":"2020022606031248900_B19","doi-asserted-by":"crossref","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Science Transl Med"},{"key":"2020022606031248900_B20","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/sj.bjc.6606072","article-title":"Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression","volume":"104","author":"Lin","year":"2011","journal-title":"Br J Cancer"},{"key":"2020022606031248900_B21","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1001\/archdermatol.2010.264","article-title":"Circulating benign nevus cells detected by ISET technique: warning for melanoma molecular diagnosis","volume":"146","author":"De Giorgi","year":"2010","journal-title":"Arch Dermatol"},{"key":"2020022606031248900_B22","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40425-014-0042-0","article-title":"Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade","volume":"2","author":"Lipson","year":"2014","journal-title":"J Immunother Cancer"},{"key":"2020022606031248900_B23","first-page":"16835","article-title":"Molecular in vitro diagnostic examinations\u2014specifications for pre-examination processes for venous whole blood\u2014part 3: isolated circulating cell free DNA from plasma","year":"2015","journal-title":"PD CEN\/TS"},{"key":"2020022606031248900_B24","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1038\/sj.bjc.6605371","article-title":"Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study","volume":"101","author":"Board","year":"2009","journal-title":"Br J Cancer"},{"key":"2020022606031248900_B25","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1016\/j.ejca.2011.04.013","article-title":"Enhanced detection of BRAF-mutants by pre-PCR cleavage of wild-type sequences revealed circulating melanoma cells heterogeneity","volume":"47","author":"Fusi","year":"2011","journal-title":"Eur J Cancer"},{"key":"2020022606031248900_B26","doi-asserted-by":"crossref","first-page":"42008","DOI":"10.18632\/oncotarget.5788","article-title":"Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma","volume":"6","author":"Gray","year":"2015","journal-title":"Oncotarget"},{"key":"2020022606031248900_B27","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1373\/clinchem.2014.230235","article-title":"Quantitative cell-free circulating BRAFv600e mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors","volume":"61","author":"Sanmamed","year":"2015","journal-title":"Clin Chem"},{"key":"2020022606031248900_B28","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1158\/1078-0432.CCR-15-0321","article-title":"Correlation of BRAF mutation status in circulating-free DNA and tumor and association with clinical outcome across four BRAFi and MEKi clinical trials","volume":"22","author":"Santiago-Walker","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2020022606031248900_B29","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-11-2696","article-title":"Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood","volume":"18","author":"Higgins","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2020022606031248900_B30","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S1470-2045(15)00138-2","article-title":"Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the correct trial","volume":"16","author":"Tabernero","year":"2015","journal-title":"Lancet Oncol"},{"key":"2020022606031248900_B31","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jmoldx.2013.12.004","article-title":"Analytical validation of BRAF mutation testing from circulating free DNA using the amplification refractory mutation testing system","volume":"16","author":"Aung","year":"2014","journal-title":"J Mol Diagn"},{"key":"2020022606031248900_B32","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1373\/clinchem.2016.254482","article-title":"Thirteen years of an international external quality assessment scheme for genotyping: results and recommendations","volume":"62","author":"Haselmann","year":"2016","journal-title":"Clin Chem"},{"key":"2020022606031248900_B33","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.cca.2011.01.014","article-title":"Brafv600e detection in melanoma is highly improved by cold-PCR","volume":"412","author":"Pinzani","year":"2011","journal-title":"Clin Chim Acta"},{"key":"2020022606031248900_B34","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12967-016-0852-6","article-title":"Quantitative assessment of BRAF v600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF\/MEK inhibitors","volume":"14","author":"Schreuer","year":"2016","journal-title":"J Transl Med"},{"key":"2020022606031248900_B35","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.molonc.2015.09.005","article-title":"Sensitivity of plasma BRAF mutant and NRAS mutant cell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression","volume":"10","author":"Chang","year":"2016","journal-title":"Mol Oncol"},{"key":"2020022606031248900_B36","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/CMR.0000000000000187","article-title":"BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors","volume":"25","author":"Gonzalez-Cao","year":"2015","journal-title":"Melanoma Res"}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/64\/5\/830\/32642285\/clinchem0830.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/64\/5\/830\/32642285\/clinchem0830.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T11:09:11Z","timestamp":1582715351000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/article\/64\/5\/830\/5608759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,1]]},"references-count":36,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2018,5,1]]},"published-print":{"date-parts":[[2018,5,1]]}},"URL":"https:\/\/doi.org\/10.1373\/clinchem.2017.281543","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,5,1]]},"published":{"date-parts":[[2018,5,1]]}}}